Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease.
Kimura M, Nishikawa K, Osawa Y, Imamura J, Yamaji K, Harada K, Yatsuhashi H, Murata K, Miura K, Tanaka A, Kanto T, Kohara M, Kamisawa T, Kimura K. Kimura M, et al. Among authors: kanto t. Hepatol Commun. 2022 Oct;6(10):2732-2747. doi: 10.1002/hep4.2043. Epub 2022 Jul 20. Hepatol Commun. 2022. PMID: 35855613 Free PMC article.
Involvement of STAT3-regulated hepatic soluble factors in attenuation of stellate cell activity and liver fibrogenesis in mice.
Shigekawa M, Takehara T, Kodama T, Hikita H, Shimizu S, Li W, Miyagi T, Hosui A, Tatsumi T, Ishida H, Kanto T, Hiramatsu N, Hayashi N. Shigekawa M, et al. Among authors: kanto t. Biochem Biophys Res Commun. 2011 Mar 25;406(4):614-20. doi: 10.1016/j.bbrc.2011.02.105. Epub 2011 Feb 26. Biochem Biophys Res Commun. 2011. PMID: 21356197
Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus.
Yoshio S, Kanto T, Kuroda S, Matsubara T, Higashitani K, Kakita N, Ishida H, Hiramatsu N, Nagano H, Sugiyama M, Murata K, Fukuhara T, Matsuura Y, Hayashi N, Mizokami M, Takehara T. Yoshio S, et al. Among authors: kanto t. Hepatology. 2013 May;57(5):1705-15. doi: 10.1002/hep.26182. Epub 2013 Mar 14. Hepatology. 2013. PMID: 23213063
Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
Aoki Y, Sugiyama M, Murata K, Yoshio S, Kurosaki M, Hashimoto S, Yatsuhashi H, Nomura H, Kang JH, Takeda T, Naito S, Kimura T, Yamagiwa Y, Korenaga M, Imamura M, Masaki N, Izumi N, Kage M, Mizokami M, Kanto T. Aoki Y, et al. Among authors: kanto t. J Gastroenterol. 2015 Aug;50(8):894-902. doi: 10.1007/s00535-014-1023-2. Epub 2014 Dec 14. J Gastroenterol. 2015. PMID: 25501286
Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
Shoji H, Yoshio S, Mano Y, Doi H, Sugiyama M, Osawa Y, Kimura K, Arai T, Itokawa N, Atsukawa M, Aoki Y, Fukai M, Taketomi A, Mizokami M, Kanto T. Shoji H, et al. Among authors: kanto t. Int J Cancer. 2017 Sep 1;141(5):1011-1017. doi: 10.1002/ijc.30804. Epub 2017 Jun 8. Int J Cancer. 2017. PMID: 28555943 Free article. Clinical Trial.
Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.
Kimura K, Ikoma A, Shibakawa M, Shimoda S, Harada K, Saio M, Imamura J, Osawa Y, Kimura M, Nishikawa K, Okusaka T, Morita S, Inoue K, Kanto T, Todaka K, Nakanishi Y, Kohara M, Mizokami M. Kimura K, et al. Among authors: kanto t. EBioMedicine. 2017 Sep;23:79-87. doi: 10.1016/j.ebiom.2017.08.016. Epub 2017 Aug 19. EBioMedicine. 2017. PMID: 28844410 Free PMC article. Clinical Trial.
240 results